Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-013875.pdf
0001179110-17-013875.rtf
0001179110-17-013875.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-013874.pdf
0001179110-17-013874.rtf
0001179110-17-013874.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-013739.pdf
0001179110-17-013739.rtf
0001179110-17-013739.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-17-007760.pdf
0001558370-17-007760.rtf
0001558370-17-007760.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-17-007829.pdf
0001558370-17-007829.rtf
0001558370-17-007829.xls
EX-101.INS - EX-101.INS
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-17-007320.pdf
0001558370-17-007320.rtf
0001558370-17-007320.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001179110-17-013227.pdf
0001179110-17-013227.rtf
0001179110-17-013227.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-013229.pdf
0001179110-17-013229.rtf
0001179110-17-013229.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-012517.pdf
0001179110-17-012517.rtf
0001179110-17-012517.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-012520.pdf
0001179110-17-012520.rtf
0001179110-17-012520.xls